Compare · FLGC vs NVO
FLGC vs NVO
Side-by-side comparison of Flora Growth Corp. (FLGC) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FLGC and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.10B, about 2088.3x FLGC ($93.9M).
- Over the past year, FLGC is down 68.8% and NVO is down 43.0% - NVO leads by 25.8 points.
- NVO has hit the wire 4 times in the past 4 weeks while FLGC has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 3 for FLGC).
- Company
- Flora Growth Corp.
- Novo Nordisk A/S
- Price
- $8.61-24.24%
- $43.91+0.06%
- Market cap
- $93.9M
- $196.10B
- 1M return
- +17.46%
- -4.14%
- 1Y return
- -68.77%
- -43.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 4
- Recent ratings
- 3
- 25
Flora Growth Corp.
Flora Growth Corp., a cannabis company, cultivates, processes, and supplies cannabis products to pharmacies, medical clinics, and cosmetic companies worldwide. It cultivates, processes, and supplies medicinal-grade cannabis oil, and cannabis oil extracts and related products; manufactures and sells skincare and beauty products, such as gel cleanser, eye cream, moisturizer, and hydrating mask; manufactures dermo cosmetic products; and develops and sells pharmaceutical and over-the-counter products, including dietary supplements, phytotherapeutic and nutraceutical products, supplements, and related products. It also manufactures and sells hemp textiles products focuses on servicing the hospitality, medical, and clothing industries on a B2B basis; designs, produces, and supplies juices, chocolate, and chocolate related products to wholesale distributors, pharmacies, supermarkets, and online distributors; and offers and wellness products. The company's brand includes Mambe, Mind Naturals, Almost Virgin, Flora Lab, and Stardog Loungewear. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest FLGC
- Flora Growth Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Flora Growth Corp.
- SEC Form FWP filed by Flora Growth Corp.
- SEC Form 424B3 filed by Flora Growth Corp.
- Flora Growth Corp. Announces Name Change to ZeroStack Corp., Furthering Its Strategy as an AI-Focused Asset Management Company
- SEC Form EFFECT filed by Flora Growth Corp.
- DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
- SEC Form 3 filed by new insider Zeifman Laurence
- SEC Form S-3 filed by Flora Growth Corp.
- Flora Growth Corp. filed SEC Form 8-K: Leadership Update
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S